SUPN
Supernus Pharmaceuticals Inc
42.80$
+0.9%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +6.8% | -12.6% | +17.2% | +4.4% | -0.9% | -14.0% | +10.4% | +16.1% | +10.1% | -1.8% | +5.5% | – | |
| – | +0.1% | -16.9% | +9.9% | -1.9% | +48.4% | -39.6% | +6.7% | +12.7% | +21.3% | +1.7% | +43.9% | – | |
| – | +7.8% | -12.0% | +18.1% | +5.1% | -6.4% | -9.5% | +10.9% | +16.5% | +8.9% | -2.3% | +0.6% | – | |
| – | +3.1% | +6.8% | +5.0% | +10.9% | -1.3% | -6.0% | -17.9% | +32.8% | -5.2% | +41.7% | -25.3% | – | |
| – | +0.3% | +3.6% | +0.6% | -43.1% | +60.9% | +7.5% | +6.6% | +261.1% | -61.8% | +219.3% | -67.4% | – | |
| – | +15.5% | -10.4% | -2.0% | -8.3% | +8.0% | +13.9% | -5.4% | +71.0% | -25.1% | +10.2% | +26.3% | – | |
| – | -112.2% | – | – | +81.0% | -47.6% | -147.9% | – | -596.1% | – | -153.8% | – | – | |
| – | – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | -90.0% | -75.5% | +10,723.9% | +70.9% | -41.3% | -122.1% | – | -447.7% | – | – | – | – | |
| – | -100.7% | – | +5,266.4% | +0.9% | +71.5% | -45.8% | -197.2% | – | – | -266.9% | – | – | |
| – | – | -89.4% | +15,961.3% | +93.3% | -60.2% | -177.2% | – | -300.5% | – | – | – | – | |
| – | -28.6% | -27.2% | +135.9% | +67.1% | -30.5% | -60.7% | +113.8% | -187.2% | – | -24.3% | -246.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.